scholarly journals DREAM Interrupted: Severing MuvB from DREAM’s pocket protein inCaenorhabditis elegansimpairs gene repression but not DREAM chromatin assembly

2019 ◽  
Author(s):  
Paul D. Goetsch ◽  
Susan Strome

AbstractThe mammalian pocket protein family, which includes the Retinoblastoma protein (pRb) and Rb-like pocket proteins p107 and p130, regulates entry into and exit from the cell cycle by repressing cell cycle gene expression. Although pRb plays a dominant role in mammalian systems, p107 and p130 represent the ancestral pocket proteins. The Rb-like pocket proteins interact with the highly conserved 5-subunit MuvB complex and an E2F-DP transcription factor heterodimer, forming the DREAM (forDp,Rb-like,E2F,andMuvB) complex. DREAM complex formation on chromatin culminates in direct repression of target genes mediated by the MuvB subcomplex. Here, we examined how the Rb-like pocket protein contributes to DREAM formation by disrupting the interaction between the soleCaenorhabditis eleganspocket protein LIN-35 and the MuvB subunit LIN-52 using CRISPR/Cas9 targeted mutagenesis. Disrupting the LIN-35-MuvB association did not affect DREAM chromatin occupancy but did cause a highly penetrant synthetic multivulval (SynMuv) phenotype, indicating that blocking DREAM assembly impairs MuvB function. Some DREAM target genes became derepressed, indicating that for those genes MuvB chromatin binding alone is not sufficient for gene repression and that direct LIN-35-MuvB association potentiates MuvB’s innate repressive activity. In a previous study we showed that in worms lacking LIN-35, E2F-DP and MuvB chromatin occupancy is reduced genome-wide. With LIN-35 present, this study demonstrates that the E2F-DP-LIN-35 interaction promotes E2F-DP’s chromatin localization, which we hypothesize supports MuvB chromatin occupancy indirectly through DNA. Altogether, this study highlights how the pocket protein family may recruit regulatory factors like MuvB to chromatin through E2F-DP to facilitate their transcriptional activity.


2000 ◽  
Vol 20 (16) ◽  
pp. 5797-5807 ◽  
Author(s):  
Julie Wells ◽  
Kathryn E. Boyd ◽  
Christopher J. Fry ◽  
Stephanie M. Bartley ◽  
Peggy J. Farnham

ABSTRACT E2F-mediated transcription is thought to involve binding of an E2F-pocket protein complex to promoters in the G0 phase of the cell cycle and release of the pocket protein in late G1, followed by release of E2F in S phase. We have tested this model by monitoring protein-DNA interactions in living cells using a formaldehyde cross-linking and immunoprecipitation assay. We find that E2F target genes are bound by distinct E2F-pocket protein complexes which change as cells progress through the cell cycle. We also find that certain E2F target gene promoters are bound by pocket proteins when such promoters are transcriptionally active. Our data indicate that the current model applies only to certain E2F target genes and suggest that Rb family members may regulate transcription in both G0 and S phases. Finally, we find that a given promoter can be bound by one of several different E2F-pocket protein complexes at a given time in the cell cycle, suggesting that cell cycle-regulated transcription is a stochastic, not a predetermined, process.



Forests ◽  
2022 ◽  
Vol 13 (1) ◽  
pp. 120
Author(s):  
Yijie Li ◽  
Song Chen ◽  
Yuhang Liu ◽  
Haijiao Huang

Research Highlights: This study identified the cell cycle genes in birch that likely play important roles during the plant’s growth and development. This analysis provides a basis for understanding the regulatory mechanism of various cell cycles in Betula pendula Roth. Background and Objectives: The cell cycle factors not only influence cell cycles progression together, but also regulate accretion, division, and differentiation of cells, and then regulate growth and development of the plant. In this study, we identified the putative cell cycle genes in the B. pendula genome, based on the annotated cell cycle genes in Arabidopsis thaliana (L.) Heynh. It can be used as a basis for further functional research. Materials and Methods: RNA-seq technology was used to determine the transcription abundance of all cell cycle genes in xylem, roots, leaves, and floral tissues. Results: We identified 59 cell cycle gene models in the genome of B. pendula, with 17 highly expression genes among them. These genes were BpCDKA.1, BpCDKB1.1, BpCDKB2.1, BpCKS1.2, BpCYCB1.1, BpCYCB1.2, BpCYCB2.1, BpCYCD3.1, BpCYCD3.5, BpDEL1, BpDpa2, BpE2Fa, BpE2Fb, BpKRP1, BpKRP2, BpRb1, and BpWEE1. Conclusions: By combining phylogenetic analysis and tissue-specific expression data, we identified 17 core cell cycle genes in the Betulapendula genome.



2020 ◽  
Author(s):  
Connor Rogerson ◽  
Samuel Ogden ◽  
Edward Britton ◽  
Yeng Ang ◽  
Andrew D. Sharrocks ◽  
...  

AbstractOesophageal adenocarcinoma (OAC) is one of the most common causes of cancer deaths and yet compared to other common cancers, we know relatively little about the underlying molecular mechanisms. Barrett’s oesophagus (BO) is the only known precancerous precursor to OAC, but our understanding about the specific events leading to OAC development is limited. Here, we have integrated gene expression and chromatin accessibility profiles of human biopsies of BO and OAC and identified a strong cell cycle gene expression signature in OAC compared to BO. Through analysing associated chromatin accessibility changes, we have implicated the transcription factor KLF5 in the transition from BO to OAC. Importantly, we show that KLF5 expression is unchanged during this transition, but instead, KLF5 is redistributed across chromatin in OAC cells to directly regulate cell cycle genes specifically in OAC. Our findings have potential prognostic significance as the survival of patients with high expression of KLF5 target genes is significantly lower. We have provided new insights into the gene expression networks in OAC and the mechanisms behind progression to OAC, chiefly the repurposing of KLF5 for novel regulatory activity in OAC.



2015 ◽  
Vol 112 (36) ◽  
pp. 11270-11275 ◽  
Author(s):  
Sadia Rahman ◽  
Mathew J. K. Jones ◽  
Prasad V. Jallepalli

The cohesin complex links DNA molecules and plays key roles in the organization, expression, repair, and segregation of eukaryotic genomes. In vertebrates the Esco1 and Esco2 acetyltransferases both modify cohesin’s Smc3 subunit to establish sister chromatid cohesion during S phase, but differ in their N-terminal domains and expression during development and across the cell cycle. Here we show that Esco1 and Esco2 also differ dramatically in their interaction with chromatin, as Esco1 is recruited by cohesin to over 11,000 sites, whereas Esco2 is infrequently enriched at REST/NRSF target genes. Esco1’s colocalization with cohesin occurs throughout the cell cycle and depends on two short motifs (the A-box and B-box) present in and unique to all Esco1 orthologs. Deleting either motif led to the derepression of Esco1-proximal genes and functional uncoupling of cohesion from Smc3 acetylation. In contrast, other mutations that preserved Esco1’s recruitment separated its roles in cohesion establishment and gene silencing. We conclude that Esco1 uses cohesin as both a substrate and a scaffold for coordinating multiple chromatin-based transactions in somatic cells.



2005 ◽  
Vol 25 (18) ◽  
pp. 8166-8178 ◽  
Author(s):  
Egle Balciunaite ◽  
Alexander Spektor ◽  
Nathan H. Lents ◽  
Hugh Cam ◽  
Hein te Riele ◽  
...  

ABSTRACT Biochemical and genetic studies have determined that retinoblastoma protein (pRB) tumor suppressor family members have overlapping functions. However, these studies have largely failed to distinguish functional differences between the highly related p107 and p130 proteins. Moreover, most studies pertaining to the pRB family and its principal target, the E2F transcription factor, have focused on cells that have reinitiated a cell cycle from quiescence, although recent studies suggest that cycling cells exhibit layers of regulation distinct from mitogenically stimulated cells. Using genome-wide chromatin immunoprecipitation, we show that there are distinct classes of genes directly regulated by unique combinations of E2F4, p107, and p130, including a group of genes specifically regulated in cycling cells. These groups exhibit both distinct histone acetylation signatures and patterns of mammalian Sin3B corepressor recruitment. Our findings suggest that cell cycle-dependent repression results from recruitment of an unexpected array of diverse complexes and reveals specific differences between transcriptional regulation in cycling and quiescent cells. In addition, factor location analyses have, for the first time, allowed the identification of novel and specific targets of the highly related transcriptional regulators p107 and p130, suggesting new and distinct regulatory networks engaged by each protein in continuously cycling cells.



Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 565-565 ◽  
Author(s):  
Andre M. Pilon ◽  
Subramanian S. Ajay ◽  
Hatice Ozel Abaan ◽  
Elliott H. Margulies ◽  
Patrick G. Gallagher ◽  
...  

Abstract Abstract 565 Erythroid Kruppel-Like Factor (EKLF; KLF1) is the founding member of the Kruppel family of C2H2 zinc finger transcription factors. First identified as an activator of the beta-globin locus, EKLF facilitates chromatin remodeling and transcriptional activation of target genes, at least in part through recognition of a 9-base consensus motif (NCNCNCCCN). By comparing the transcriptional profiles of E13.5 wild type and Eklf-/- mice, we demonstrated that the lethal failure to complete definitive erythropoiesis in the fetal liver (FL) was due in part to dysregulation of an EKLF target gene, the cell cycle control factor, E2F2 (Pilon et al. 2008). To identify further direct targets of EKLF activation that affect erythropoiesis, we are coupling chromatin immunoprecipitation with ultra high-throughput massively parallel sequencing (ChIP-seq). ChIP-seq is increasingly being used to map protein-DNA interactions in vivo, allowing simultaneous genome-wide analysis of transcription factor occupancy, defining an ‘interactome‘. Using mice whose endogenous Eklf gene was replaced with a fully functional HA-tagged form of EKLF, chromatin was isolated at E13.5 from immature erythroid progenitors and maturing erythroblasts by ChIP. Using a highly specific high-affinity anti-HA antibody, libraries of HA-EKLF-bound chromatin were subjected to fluorescent in situ sequencing on a Solexa 1G platform, providing 36-base signature tags that were mapped to the mouse genome using the Eland software package. A control library was derived from E13.5 FL chromatin that was not enriched for HA-EKLF occupancy. For both progenitors and erythroblasts, >1.1×107tags were obtained. 72.5% and 78.7% of progenitor and erythroblast tags mapped to unique sites within the genome, respectively. The tags were highly enriched in the ∼10% of the genome within genes (genic; 42% of tags), sites ≤10 kb from the nearest gene (adjacent; 15%), as opposed to the ∼90% of the genome that is >10 kb from the nearest gene (intergenic; 22%) or in repetitive DNA (21%) p=2.2 ×10-16. Using the MACS software package clustered peaks of EKLF occupancy were identified throughout the genome, defining the EKLF ‘interactome‘. The vast majority of peaks were mapped to non-repetitive regions of the genome (98% in progenitors; 95% in erythroblasts). Progenitors contained 4,383 peaks of EKLF occupancy, while erythroblasts contained 15,396 peaks. Only 100 peaks were common between populations. This >3.5-fold increase in genomic EKLF occupancy between progenitors and erythroblasts (p=1×10-5) reflects the shift in the expression and activity of EKLF protein in erythropoiesis described previously (Bouilloux et al. 2008; Lohmann & Bieker 2008). To identify potential EKLF target genes, we partitioned the genome into 3 categories, relative to annotated RefSeq coordinates (genic) as well as adjacent and intergenic. In progenitors, the majority of EKLF binding (54%) occurred in intergenic regions, with a minority within (38%) or adjacent (7%) to genes. By contrast, the EKLF binding profile in erythroblasts was reversed, with 62% of the peaks in genic regions, and a minority at intergenic (26%) or adjacent (12%) sites.To assess the effect of this shift in EKLF binding on gene transcription, we used publicly availabel data from the inducible G1E model of erythroid maturation (GEO: GSE628) to correlate our ChIP-seq data with mRNA expression. Informatic analyses using MetaCore demonstrated that >2,200 EKLF-associated genes were differentially expressed during maturation (949 increasing expression; 1,298 decreasing expression, all p<0.05). Among progenitors, control of cell cycle S-phase entry and progression was a significantly represented network, highlighted by focal EKLF target genes like Cdk2, Cdk4, and p107, in agreement with our previous observations. Among erythroblasts, the erythropoietin (Epo) signaling pathway was most significantly represented, highlighted by focal EKLF target genes like Stat3 and Bcl-XL, reflecting the well-established importance of the Epo axis for erythroblast survival. These data indicate that shifts in EKLF occupancy during erythropoiesis correlate with distinct functional effects on gene expression. Further, these observations support a model in which transcriptional regulators (e.g., EKLF) may collect at intergenic locations when their activity is not required, but where they remain poised for rapid recruitment. Disclosures: No relevant conflicts of interest to declare.



Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1845-1845
Author(s):  
Mariateresa Fulciniti ◽  
Manoj Bashin ◽  
Mehmet Kemal Samur ◽  
Rajya Bandi ◽  
Parantu K Shah ◽  
...  

Abstract Transcription factors (TFs) are important oncogenic regulator and are altered during tumor initiation and progression. Our oncogenomic analysis of gene expression data from large clinically-annotated patient samples identified TF Dp1 as one of the most important gene affecting both overall and event-free survival in multiple myeloma (MM). Elevated Dp1 expression was predictive of adverse clinical outcome, independent of Dp1 protein partners, E2Fs and RB, suggesting direct impact of Dp1 and providing the rationale to further evaluate its specific role in MM. We have observed high level of Dp1 expression and activity in MM cells which was further induced after interaction with bone marrow stromal cells (BMSC). Moreover, Dp1 knock-down using specific sh-RNA decreased MM cell growth in 5 MM cell lines with different genetic background, with a concomitant G1 arrest and late induction of apoptosis. These data suggest a role for Dp1 in MM cell proliferation and survival and established a rationale to identify its molecular impact. We have further characterized Dp1 activity using chromatin immunoprecipitation with Dp1 or E2F1 specific antibody followed by genome wide sequencing (ChIP-Seq) to identify Dp1-binding regions in MM. We have identified 2783 exclusive Dp1 binding regions in two MM cell lines. Examination of Dp1 and E2F1 binding revealed that Dp1 co-occupies 65% of the binding sites with E2F1. The DAVID gene set enrichment analysis showed that identified genes were related to cell cycle, as well as to transcriptional and translational processes. To assess the functional consequences of Dp1 DNA binding, the ChIP-Seq data were supplemented with gene expression profile of MM1S cells following shRNA-mediated Dp1 and E2F knock-downs. Integrated analysis incorporating ChIP-seq and expression data identified Dp1 response program in MM. 805 (46%) of 1752 differentially expressed genes also have binding sites for Dp1 and likely are direct transcriptional targets of Dp1 in MM. Enrichment analysis of direct targets revealed that the most strongly enriched pathways for both Dp1 and E2F1 genes combined were related to the cell cycle, especially DNA replication, repair, and metabolism. Interestingly, pathway analysis identified ‘‘regulation of RNA metabolic processes’’ (40 target genes), ‘‘RNA processing’’ (93 target genes) ‘‘RNA splicing’’ (95 genes), and ‘‘RNA binding’’ (53 genes) as statistically significant RNA-related categories enriched among Dp1 target genes, suggests role of Dp1 in RNA splicing. Based on our previous data showing that dysregulated alternate splicing (AS) has significant impact on overall clinical outcome MM, we evaluated the expression of Dp1-modulated splicing factors in our clinically annotated cohort of MM patients and 5 normal PCs. We identified 23 SFs upregulated in MM compared to normal plasma cells. Importantly, the increased expression of 12 of these SFs was linked with poor prognosis in this cohort of myeloma patients. Our data show for the first time that SFs are upregulated in myeloma and link to clinical outcome. To evaluate the impact of Dp1 on alternate splicing (AS), we performed genome-wide analysis of alternate splicing in total RNA from Dp1 silenced MM1S cells using Human Exon1 ST arrays. Splicing profiles showed that Dp1 knock down causes widespread changes in AS. We have identified 3683 genes whose one exon has splicing index more than 1.5 in in shDP1 compared to control pLKO.1-transduced MM1S cells, suggesting impact of Dp1 silencing on alternate splicing. We are now evaluating impact of a peptide able to disrupt Dp1-E2F1 binding with consequent effect on MM cell growth and alternate splicing. In conclusion, our investigation showed that the Dp1/E2F1 signaling pathway plays significant role in myeloma and can directly activate transcription of specific SFs with effect on alternate splicing and potential functional, clinical and therapeutic implications in myeloma. Disclosures: No relevant conflicts of interest to declare.



2021 ◽  
Vol 11 ◽  
Author(s):  
Audra N. Iness ◽  
Lisa Rubinsak ◽  
Steven J. Meas ◽  
Jessica Chaoul ◽  
Sadia Sayeed ◽  
...  

Cell cycle control drives cancer progression and treatment response in high grade serous ovarian carcinoma (HGSOC). MYBL2 (encoding B-Myb), an oncogene with prognostic significance in several cancers, is highly expressed in most HGSOC cases; however, the clinical significance of B-Myb in this disease has not been well-characterized. B-Myb is associated with cell proliferation through formation of the MMB (Myb and MuvB core) protein complex required for transcription of mitotic genes. High B-Myb expression disrupts the formation of another transcriptional cell cycle regulatory complex involving the MuvB core, DREAM (DP, RB-like, E2F, and MuvB), in human cell lines. DREAM coordinates cell cycle dependent gene expression by repressing over 800 cell cycle genes in G0/G1. Here, we take a bioinformatics approach to further evaluate the effect of B-Myb expression on DREAM target genes in HGSOC and validate our cellular model with clinical specimens. We show that MYBL2 is highly expressed in HGSOC and correlates with expression of DREAM and MMB target genes in both The Cancer Genome Atlas (TCGA) as well as independent analyses of HGSOC primary tumors (N = 52). High B-Myb expression was also associated with poor overall survival in the TCGA cohort and analysis by a DREAM target gene expression signature yielded a negative impact on survival. Together, our data support the conclusion that high expression of MYBL2 is associated with deregulation of DREAM/MMB-mediated cell cycle gene expression programs in HGSOC and may serve as a prognostic factor independent of its cell cycle role. This provides rationale for further, larger scale studies aimed to determine the clinical predictive value of the B-Myb gene expression signature for treatment response as well as patient outcomes.



Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3465-3465
Author(s):  
Irina Velichutina ◽  
Rita Shaknovich ◽  
Huimin Geng ◽  
Ari Melnick ◽  
Olivier Elemento

Abstract Abstract 3465 Poster Board III-353 EZH2 is the catalytic subunit of the PRC2 Polycomb complex and mediates transcriptional repression through its histone methyltransferase activity. It is over-expressed in many types of aggressive tumors, e.g., prostate and breast cancer and this over-expression is generally associated with poor patient prognosis. It is also over-expressed in certain lymphomas, e.g., follicular lymphoma; however its exact role and importance in normal and malignant B-cells remains unclear. Most B-cell lymphomas arise from germinal center (GC) B-cells. We thus first set out to investigate the function and activity of EZH2 in normal B-cells. We confirmed a previously published observation that expression of EZH2 protein is greatly elevated during developmental transition from resting Naive B-cells to rapidly proliferating GC B-lymphocytes. Using ChIP-on-chip, we then determined the genome-wide pattern of EZH2 binding in GC B cells and found that EZH2 targets ∼1,800 promoters in these cells (at FDR<0.1). We also mapped the genome-wide distribution of H3K27me3 histone marks in GC B cells; consistent with the known role of EZH2 in catalyzing H3K27me3, a majority (62%) of EZH2 target promoters also displayed a very strong H3K27me3 peak (p=0, hypergeometric test). Also consistent with the repressive nature of H3K27me3, expression arrays rezvealed that EZH2 targets are usually expressed at a lower level in GC B cells than other genes (p<1e-80). However, contrary to a previously postulated role of EZH2 in promoting DNA methylation, our results indicate that EZH2-bound promoters are largely hypomethylated in GC B cells (p=0, Wilcoxon test). From the biological standpoint EZH2 target genes are enriched with transcription factors (p<1e-5), kinases (p<1e-6), and other components of signal transduction pathways such as TGF-beta, WNT, EGFR, PDGFR, and VEGF. EZH2 also targets and represses many tumor suppressor genes, e.g., CDKN1A/p21 and CDKN1B/p27, CDKN2A/p16 and CDKN2A/p14. Using an unbiased motif discovery procedure, we associate EZH2 binding with sequences highly similar to those bound by orthologous PRC2 in Drosophila; we find that EZH2 binding is also associated with the highly statistically significant depletion of regulatory sequences typically bound by transcriptional activators. We then compared the genome-wide binding patterns of EZH2 in GC B cells and embryonic stem cells and observed a strong overlap of EZH2 targets between these cell types (>30% of GC B cells targets are also bound in hESCs, p<1e-378). However, we also observed a large GC B cell-specific EZH2 regulatory program with >1,000 genes. Seeking to extrapolate our binding data to GC-derived Diffuse Large B Cell Lymphoma (DLBCL), we found that the expression profile of many EZH2 target genes is anti-correlated with EZH2 mRNA levels in expression profiles of primary DLBCL tumors. Surprisingly, we found that this anti-correlation was most pronounced among GC B cell-specific EZH2 targets (p<1e-26). In turn, the EZH2 mRNA level was itself positively correlated with cellular proliferation in primary DLBCL tumors, as measured by Ki67 staining (Pearson correlation = 0.3, p<0.001). Finally siRNA-mediated down-regulation of EZH2 in SUDHL4 DLBCL cells resulted in acute cell cycle arrest at the G1/S transition in SUDHL4 cells and upregulation of EZH2 target genes with cell cycle inhibitory functions such as those mentioned above. Altogether, these data suggest a scenario whereby EZH2 upregulation in GC B-cells leads to its recruitment to genes containing Polycomb Response Elements with consequent H3K27 trimethylation and silencing of a GC B cell context specific cohort of genes including those involved in restraining cellular proliferation, thus contributing to the ability of these cells to undergo massive clonal expansion. This function of EZH2 may also contribute to the malignant transformation of GC B-cells into DLBCLs and facilitate their proliferative phenotype. Thus, our results indicate that therapeutic targeting of EZH2 might have significant anti-lymphoma effects and support the rationale for development of inhibitors of the EZH2 SET domain. Disclosures No relevant conflicts of interest to declare.



Sign in / Sign up

Export Citation Format

Share Document